Click here to view the presentation slides from this CME-certified program. (coming soon)
Click here to view the presentation slides from this CME-certified series held at select American College of Radiology (ACR) state chapter meetings.
Although atopic dermatitis (AD) is 2 to 3 times more prevalent than psoriasis, there have not been significant improvements in the management of this serious condition for decades. Available treatments do not address the underlying pathophysiology and contribute to a vicious cycle of nonadherence and disease progression. Patients and providers are dissatisfied and frustrated with the poor efficacy of topical agents and adverse events associated with broad-spectrum immunosuppressants.
An improved understanding of AD pathogenesis has led to the development of new treatments that target the Th2-polarized immune system, which plays a key role in the symptoms of AD and progression of the atopic march to more severe skin disease and respiratory allergic conditions. A new proactive, evidence-based, immunologically founded treatment approach allows patients to be more in control of their disease and actively involved in its management.
This CME activity will help allergists and dermatologists become more familiar with new treatment options for AD, and will discuss how emerging biomarkers in AD have the potential to enhance individualization of therapy, by targeting a patient's specific biological signatures, and help predict and monitor therapeutic response. Clinicians will be provided with strategies to educate their patients, facilitate acceptance of therapies, promote self-management, achieve disease control and ultimately prevent patients from progressing along the atopic march.
Welcome and Introductions
Pathophysiologic Pathways, the Atopic March, and the Promise of New Treatment Options
Importance of Early AD Diagnosis and Severity Assessment to Guide Appropriate Treatment
New Treatment Approaches – Achieving New Treatment Goals
Q&A Session and Closing Remarks
This activity is intended for dermatologists, dermatology nurse practitioners/physician assistants, allergists, and other clinicians involved in the management of atopic dermatitis (AD).
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Recognize the importance of targeting the underlying pathophysiology of AD that is driven by abnormal type 2 immune responses
- Summarize the role of type 2 immune response in the pathophysiology of AD and the atopic march
- Recognize hallmark signs and symptoms of AD to ensure early diagnosis
- Apply appropriate assessments to determine disease severity
- Explain how emerging systemic treatments for AD can improve management of the disease and its comorbidities, while considering MOAs, safety and efficacy profiles, indications, and impacts on AD biomarkers and disease progression
Joel M. Gelfand, MD, MSCE
Professor of Dermatology
Professor of Epidemiology
Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Joel M. Gelfand, MD, MSCE
is Professor of Dermatology and Epidemiology (with tenure) at the University of Pennsylvania’s Perelman School of Medicine. He is also Vice Chair of Clinical Research and Medical Director of the Dermatology Clinical Duties Unit, Director of the Psoriasis and Phototherapy Treatment Center, and Founding Director of the Patient Centered Outcomes Research concentration in the university’s Graduate Epidemiology Master Degree program. Dr. Gelfand is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials. He has received grant support from the National Institutes of Health (NIH), the Dermatology Foundation, the American Skin Association, the National Psoriasis Foundation, and numerous pharmaceutical companies to support his independent research. The overarching goal of his research and clinical practice is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, CV disease, and mortality.
He is also Principal Investigator of 3 large NIH-funded psoriasis projects: the Dermatology Clinical Effectiveness Research Network (DCERN), which evaluates the effectiveness of psoriasis treatments under real-world conditions; the Incident Health Outcomes and Psoriasis Events (iHOPE) study, which is a population-based prospective study of 9,000 psoriasis patients and 90,000 controls; and the Vascular Inflammation in Psoriasis Trials (VIP), which are multi-center interventional trials evaluating the impact of a adalimumab, secukinumab, ustekinumab, phototherapy, and placebo on vascular inflammation and lipid metabolism.
Dr. Gelfand is the author of more than 100 scientific publications in journals such as JAMA, BMJ, European Heart Journal, Annals of Rheumatic Disease, JAMA Dermatology, JAAD, and the JID. He is the recipient of the American Skin Association’s Psoriasis Achievement Award, PENN’s Marjorie Bowman Award, Penn’s Department of Biostatistics and Epidemiology’s Epidemiology Teaching Award, and is an elected member of the American Society for Clinical Investigation.
Jonathan M. Spergel, MD, PhD
Professor of Pediatrics
Chief, Allergy Section
Stuart E. Starr Chair of Pediatrics
Director of Center for Pediatric Eosinophilic Disease
The Children's Hospital of Philadelphia
Perelman School of Medicine at Univ. of Pennsylvania
Jonathan M. Spergel, MD, PhD is a Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the Allergy Section at Children’s Hospital of Philadelphia. He is also holder of the Stuart Starr Chair of Pediatrics and Director of the Center for Eosinophilic Diseases. He received his medical and graduate education at the Mount Sinai School of Medicine and completed his pediatric residency at Yale-New Haven Hospital. His clinical and post-graduate research training in allergy and immunology were completed at Children’s Hospital, Harvard Medical School, Boston, MA. Dr. Spergel is board Ccrtified in pediatrics and allergy and immunology. He is a Fellow of the American Academy of Allergy Asthma and Immunology (AAAAI); American College of Allergy, Asthma and Immunology; American Association of Pediatrics; Philadelphia College of Physicians; and others. He has severed on national and international committees on food allergy, atopic dermatitis, and eosinophilic esophagitis. Dr. Spergel is the Principal Investigator for multiple studies in the fields of atopic dermatitis, eosinophilic esophagitis, and food allergies. He has published more than 130 articles in the field. He has spoken nationally and internationally in the fields of eosinophilic esophagitis, food allergies and atopic dermatitis.
His current research focuses on both clinical (desensitization and tolerance) in eosinophilic esophagitis and food allergy and translational research (molecular mechanisms in eosinophilic esophagitis and the role of fibrosis, iNKT cells, microbiome and genetic pathways.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email email@example.com.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Method of Participation
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided after submission of a completed evaluation form.
There is no fee associated with this program.
Event staff will be glad to assist you with any specials needs. Please email firstname.lastname@example.org at least 5 days prior to the program.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This activity has been supported through an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.